ARTICLE | Clinical News

Euthymics' EB-1010 meets depression endpoint

December 9, 2010 12:10 AM UTC

Euthymics Bioscience Inc. (Cambridge, Mass.) said EB-1010 met the primary endpoint vs. placebo in a Phase II trial to treat major depressive disorder (MDD). In the modified intent-to-treat population of 56 patients, EB-1010 significantly improved Montgomery-Asberg Depression Rating Scale total score at week six vs. placebo (18.16 vs. 21.99 points, p=0.028). Data were presented at the American College of Neuropsychopharmacology meeting in Miami. ...